Home
overview
Congestive heart failure (CHF) is a major health issue, it is the leading cause of hospitalisation of the over 65’s in the US and has an unacceptably high morbidity. Current polypharmacy treatment regimens do prolong and improve quality of life however CHF therapies still fall far short of the clinical need.

Fortunately recent advances in molecular biology have greatly improved understanding of the disease and are assisting in the hunt for new therapeutics. Targets such as kinases, ion channels and specific receptors all look to be promising and the range of targets currently under investigation in the pharmaceutical industry has greatly increased.

As a senior industry executive, you will be aware of the importance and potential of this field. We would therefore like to invite you to register for SMi’s Cardiovascular Summit 2000: Heart Failure Drugs. As you will see from the brochure, the standard of speakers from both the biotechnology and pharmaceutical sectors makes this an unmissable event.

Please register now to guarantee your place at this important conference.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Prof John Cleland

Prof John Cleland, Foundation Chair in Cardiology, University of Hull

9:10 DIRECTIONS IN CARDIOVASCULAR DRUGS

Dr Norbert Bender

Dr Norbert Bender, Head, Cardiovascular, Clinical Research, BASF

  • Efficacy of current treatments
  • Unmet clinical needs in congestive heart failure and hypertension
  • Effectiveness of polypharmacy approaches
  • Inflammatory processes: an important role in cardiovascular disease?
  • Directions in developing treatments aimed at established targets
  • What is the potential for identification of new targets?
  • 9:40 MYOCYTE APOPTOSIS: IMPLICATIONS FOR DRUG DEVELOPMENT

    Dr Stephen Mento

    Dr Stephen Mento, President & CEO, Idun Pharmaceuticals

  • Is myocyte apoptosis a cause or an effect of CHF?
  • Molecular pathways implicated in myocyte apoptosis
  • Potential targets arising from the elucidation of the molecular pathways
  • Impact of current therapeutics on myocyte apoptosis
  • Using myocyte apoptosis as a prognostic indicator
  • 10:20 GENE THERAPY FOR HEART FAILURE

    Dr H Kirk Hammond

    Dr H Kirk Hammond, Professor of Medicine, USCD, Scientific Founder & Chief Scientist, Collateral Therapeutics

  • Rationale for new paradigms for the treatment of heart failure
  • Adenylate Cylcase as a candidate for gene therapy for heart failure
  • FGF4 gene therapy for heart failure
  • Clinical trials using non-surgical cardiovascular gene therapy
  • 11:00 Morning Coffee

    11:20 SERCA2A AS A THERAPEUTIC TARGET

    Dr Sian Harding

    Dr Sian Harding, Reader in Cellular Pharmacology, Imperial College School of Medicine

  • Role of SERCA2a in cardiac excitation-contraction coupling
  • Evidence that reduced activity of SERCA2a is central to changes in myocardial contraction in failing human heart
  • Gene transfer of SERCA2a into human and animal isolated cardiac myocytes using adenoviral vectors
  • Increased expression if SERCA2a reverses failure-induced contractile change sin human myocytes
  • Contrasting effects of SERCA2a overexpression with -adrenoceptor stimulation on arrhythmogenesis
  • 12:00 TARGET IDENTIFICATION

    Dr Andrés Negro-Vilar

    Dr Andrés Negro-Vilar, Senior Vice President, R & D, Chief Scientific Officer, Ligand Pharmaceuticals

  • Introduction to recent advances in nuclear receptor technology gene identification
  • Nuclear receptor co-factors and tissue selectivity
  • Gene identification strategies
  • How are these technologies being applied to cardiovascular research?
  • 12:40 Lunch

    13:40 ENDOTHELIN ANTAGONISTS

    Dr Richard Dixon

    Dr Richard Dixon, Senior Vice President, Research, Texas Biotechnology

  • Slowing the rate of disease progression
  • Pathways involved in myocardial remodelling
  • Elucidating the role of endothelin myocardial remodelling
  • Endothelin signalling as a target for CHF drugs
  • Development of TB11251
  • 14:20 ANTI-INFLAMMATORY COMPOUNDS

    Dr Douglas Williams

    Dr Douglas Williams, Executive Vice President, Chief Technology Officer, Immunex

  • History of Enbrel and it’s success in rheumatoid arthritis
  • Role of inflammation in heart failure
  • Mechanism of action of Enbrel: anti-TNF
  • Clinical data for Enbrel in heart failure patients
  • Future directions for the research
  • 15:00 METALLOPROTEINASE INHIBITORS

    Dr Mark Perrone

    Dr Mark Perrone, Executive Director, Cardiovascular, Bristol Myers Squibb

  • Mechanism of action of omapatrilat
  • Preclinical data
  • Clinical experience with omaptrilat
  • 15:40 Afternoon Tea

    16:00 MEMBRANE TRANSPORTERS AS TARGETS

    Dr Antoine Bril

    Dr Antoine Bril, Director, Cardiovascular Pharmacology, SmithKline Beecham

  • Mechanism of regulation of myocyte pH
  • The sodium proton exchanger
  • The sodium bicarbonate cotransporter
  • Methods to determine the role of these transporters in CHF
  • Proposed role of membrane transporters in the development of CHF
  • Applying this knowledge to the development of new drugs
  • 16:30 DIAGNOSING HEART FAILURE

    Dr George Jackowski

    Dr George Jackowski, President & Chief Scientific Officer, Syn X Pharma

  • Problems in the diagnosis of CHF and the need for a POC test
  • Identification of ANF and BNP
  • Development of a diagnostic test using protein markers
  • Market value for a CHF test
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    17:40 Networking drinks reception for delegates and speakers

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Desmond Fitzgerald

    Dr Desmond Fitzgerald, Visiting Professor, University of Strathclyde

    9:10 INTEGRATIVE BIOLOGY

    Dr Desmond Fitzgerald

    Dr Desmond Fitzgerald, Visiting Professor, University of Strathclyde

  • The relevance of integrative biology in the genomic area
  • Integrative biology and complex systems
  • Its role in candidate drug selection in cardiovascular research
  • Future trends and obstacles
  • 9:40 ADVANCES IN TECHNOLOGY

    Dr Patrick Kleyn

    Dr Patrick Kleyn, Chief Scientific Officer, Gemini Genomics

  • Clinical genomics: the primary source of novel gene-based targets
  • Diverse human populations: the raw material for gene identification
  • Comprehensive clinical information: dissecting complex disorders
  • Detailed genetic data: searching for common variation
  • Bioinformatics: identifying disease-gene associations
  • From gene to target: unlocking the therapeutic potential
  • 10:20 FROM GENES TO CARDIOVASCULAR THERAPEUTICS

    Dr Paul Eisenberg

    Dr Paul Eisenberg, Acting Vice President, Cardiovascular Discovery & Clinical Investigation, Eli Lilly

  • Identification of targets: too many targets and too little time?
  • Identifying the best target from the plethora of choice
  • Methods to elucidate the role of and the signalling cascades of potential targets
  • Moving from target to patentable ligand
  • Individualised medicine, is this the way forward for cardiovascular therapies?
  • Molecular cardiovascular programmes underway at Eli Lilly
  • 11:00 Morning Coffee

    11:20 TRANSLATION OF THE TARGET INTO CLINICAL DEVELOPMENT

    Dr Milton Pressler

    Dr Milton Pressler, Senior Director, Clinical Research, Cardiovascular, Parke Davis

  • Potential hurdles in clinical trials for heart failure drugs
  • Identifying the right patient group
  • Determining effective end points for heart failure drugs
  • Added complications with other cardiac problems
  • Research directions at Parke Davis
  • 12:00 COMBATING AGE RELATED HEART DISESASE

    Dr John Egan

    Dr John Egan, Executive Director, Licensing & Technology Development, Alteon

  • The role of Advanced Glycosylation End-product (A.G.E) crosslinks in the pathophysiology of heart disease
  • Pre-clinical development of ALT-711
  • Mechanism of action of ALT-711: A.G.E crosslink breakage
  • Clinical development of ALT-711 and impact on the aged cardiovascular system
  • Other potential clinical applications
  • 12:40 Lunch

    13:40 AN UPDATE ON IMMUNOTHERAPIES

    Dr Arthur Rushton

    Dr Arthur Rushton, Chief Operating Officer, Proteus International

  • Why use immunotherapies in cardiovascular disease?
  • Development of peptide conjugate vaccines
  • Targeting the renin-angiotensin system with immunotherapeutics
  • Other immunotherapeutic targets with potential for cardiovascular disease
  • Clinical evidence for the efficacy of vaccines in cardiovascular disorders
  • 14:20 PROTEOMICS AS A RESEARCH TOOL

    Alison Pearce

    Alison Pearce, Business Development Manager, Proteome Sciences

  • Introduction to proteomics
  • How powerful is this as a target identification tool?
  • Application of proteomics to chronic heart disease and chronic rejection after heart transplantion
  • Current research directions at Proteome Sciences
  • 15:00 CURAGEN & COR THERAPEUTICS: IDENTIFICTION OF PLATELET AND ENDOTHELIAL CELL GENES

    Dr Fuad Mehraban, Senior Research Scientist, Discovery Research, CuraGen Corporation

    Dr Fuad Mehraban, Senior Research Scientist, Discovery Research, CuraGen Corporation, , Dr James Topper, Vice President, Biology, COR Therapeutics

  • Rapid generation of human platelet and endothelial cell expressed gene databases
  • Methods focused on protein coding regions
  • Identification of predicted secreted, membrane-associated, and signalling molecules as potential drug targets
  • High-throughput differential expression profiling using an open-architecture system
  • Focus on the identification of novel vascular genes modulated by various stimuli
  • Identification of protein interactions and pathway analysis using a high-throughput yeast 2-hybrid system
  • 15:40 Afternoon Tea

    16:00 A NEW MODEL TO WORK FROM

    Dr Giora Feuerstein

    Dr Giora Feuerstein, Senior Director, Cardiovascular Diseases Research, DuPont Pharmaceuticals

  • Myocardial dysfunction: a progressive disorder
  • Systems involved in myocardial re-modelling
  • Sympathetic nervous system
  • Neurohormonal systems
  • Viability of these systems as potential drug targets
  • 16:00 CASE STUDY: FATTY ACID OXIDATION INHIBITORS

    Dr Hani Sabbah

    Dr Hani Sabbah, Director, Cardiovascular Research, Henry Ford Health System

  • Myocardial metabolism
  • Inhibition of fatty acid oxidation
  • Heart failure
  • Left ventricular performance
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Effective Use of Imaging in Cardiovascular Drug Discovery & Development
    Workshop

    Effective Use of Imaging in Cardiovascular Drug Discovery & Development

    The Hatton, at etc. venues
    4th October 2000
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.